...A. We've invested $1 billion. B. It also helps us with our industry-leading 70-plus percent gross margins are accelerating operating margin and ultimately, free cash flow generation. C. Cologuard Plus, which is the next generation of noninvasive colon cancer screening. D. Cologuard for colon cancer screening and Oncotype DX, which is an essential test to help guide early breast cancer patients to answer the question, should they get chemotherapy or not? E. Most of the patients HR-positive, HER2-negative, a large subclass of breast cancers, the largest subclass in breast cancer patients get only about 20% benefit from chemotherapy. F. Oncotype DX definitively answers the question, which 20%. G. Allowing over the last 20 years, patients to move away from chemotherapy about 80% don't need chemotherapy and 20%, so many who thought maybe they didn't need chemotherapy actually do. H. And we expect to add about 100 new health systems a year into the exact Nexus ecosystem. I. 75% of all of our...
